Blood serum amino acid pool violation of in patients with liver cirrhosis
Objective. To investigate serum amino acid pool changes in patients with liver cirrhosis.
Materials and methods. 95 patients with liver cirrhosis were participated in the study. In the 1st group (class A disease severity according to Child- Pugh score) there were 18 (18.95%) patients, in the 2nd group (class B) - 25 (26.3%), in the 3rd groups (class C) - 52 (54.7%) patients. The amount of free amino acids in blood serum was determined by reversed-phase high-performance liquid chromatography in isocratic elution mode with electrochemical detection.
Results. Violations of free amino acid reserves were revealed in patients with cirrhosis of the liver with a predominant accumulation of aromatic amino acids: phenylalanine - (162.45 ± 14.12) nmol/ml, tyrosine - (99.05 ± 10.07) nmol/ml, tryptophan - (76.10 ± 12.40) nmol/ml, as well as an increase in the content of proline, lysine, cysteine (p <0.05) . In parallel, the decreasing of free serum amino acids with branched side chain levels were observed: valine - up (150.10 ± 8.92) nmol/ml leucine - up (75.14 ± 5.12) nmol/ml (p < 0.05) and isoleucine - up to (80.40 ± 8.01) nmol/ml.
Conclusions. The correlation between the second degree of thick guts dysbiosis and increased levels of tryptophan was determined (r = 0.77; p <0.01). III degree thick dysbiosis was correlated with increasing levels of phenylalanine (r = 0.71; p <0.01). In patients of 2nd group the correlations between levels of tryptophan and II degree of intestinal dysbiosis (r = 0.58; p <0.01) and the levels of tyrosine in phenylalanine in III stage intestinal dysbiosis were detected.
Chen Y, Guo J, Qian G, Fang D, Shi D, Guo L, Li L. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol. 2015 Sep;30(9):1429-37. doi: 10.1111/jgh.12932. PMID: 25711972.
Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2020 Sep 30:gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470. Epub ahead of print. PMID: 32998876.
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005 Feb;115(2):209-18. doi: 10.1172/JCI24282. Erratum in: J Clin Invest. 2005 Apr;115(4):1100. PMID: 15690074; PMCID: PMC546435.
Orloff MJ, Bell RH Jr, Orloff MS, Hardison WG, Greenburg AG. Prospective randomized trial of emergency portacaval shunt and emergency medical therapy in unselected cirrhotic patients with bleeding varices. Hepatology. 1994 Oct;20(4 Pt 1):863-72. doi: 10.1002/hep.1840200414. PMID: 7927227.
Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014 Dec;61(6):1385-96. doi: 10.1016/j.jhep.2014.08.010. Epub 2014 Aug 15. PMID: 25135860.
Nedashkivskyi SM. Drug-induced liver damage:principles of diagnosis, pathological changes and treatment approaches. Emergency Medicine. 2019;(2):63-70. Ukrainian. DOI: 10.22141/2224-05220.127.116.119.161644.
Meldekhanov TT, Imanbekova JA, Kuttybaev AD, Terlikbaeva GA. Hpatic encephalopathy: cognitive dysfunction, clinical manifestations, pathogenesis, pathophysiological principles of therapy. Vestnik KazNMU. 2019;(1):261-6. Kazakh.
Dam-Larsen S, Franzmann M, Christoffersen P, Larsen K, Becker U, Bendtsen F. Histology and prognosis in fatty liver patients. J Hepatol.2004;40(Suppl 1):170. doi:10.1016/S0168-8278(04)90581-8.
Rusyn VI, Sirchak EU, Koval GM, Malyar-Gazda NM, Petrychko OI. Hepatic encephalopathy in patients with liver cirrhosis. Kharkiv: Golden Pages; 2015. 165 p. Ukrainian. ISBN 978-966-400-328-2.
Sirchak YeS, Griga VI, Pichkar YoI, Gema-Bagina NM. Correction of Colon Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Ukr J Med Biol Sport. 2019;4(5):186-91. Ukrainian. doi: 10.26693/jmbs04.05.186
This work is licensed under a Creative Commons Attribution 4.0 International License.